Key Record Dates Identifier: NCT03067285
Brief Title: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (DREAM)

First Submitted : February 14, 2017
First Submitted that Met QC Criteria : February 24, 2017
First Posted : March 1, 2017

Last Update Submitted that Met QC Criteria : August 26, 2019
Last Update Posted : August 27, 2019 (Estimate)